<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361841</url>
  </required_header>
  <id_info>
    <org_study_id>CHUS-09-184</org_study_id>
    <nct_id>NCT01361841</nct_id>
  </id_info>
  <brief_title>Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma</brief_title>
  <official_title>Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraocular pressure (IOP) is considered to be the main risk factor for progression of
      glaucoma and therefore the main target of therapy. Pharmacologic treatment of glaucoma has
      changed considerably during the last decades due to the introduction of prostaglandin
      analogues. Three of these are commonly used in North America: latanoprost (Latanoprost T,
      Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).

      There have been several studies to evaluate their effectiveness. The three seem to be
      equivalent, according to the only study that has compared the molecules. Latanoprost is
      employed initially, due to its paucity of side effects when compared to the other two
      analogues. However, if it is not effective, several studies ahve shown that a result is
      possible using either travoprost or bimatoprost. No study has been conducted to date
      systematically comparing the three molecules in cases of resistance to latanoprost. In
      actuality, the investigators patients will receive treatment identical to current practice
      with the exception of the group continuing with latanoprost. Several studies confirm the
      benefit of changing prostaglandin analogues if the first has not signficantly decreased the
      IOP (Palmberg et al. 2004). Each prostaglandin has unique properties which may cause the
      mechanism of action to vary slightly among patients. (cf. Pharmacological Aspects)

      The goal of the study is thus to evaluate the efficaciousness of latanoprost, bimatoprost and
      travoprost in their IOP-lowering capacity in patients who do not initially respond to
      latanoprost.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research question:

      What is the effectiveness of latanoprost, bimatoprost and travoprost in patients whose
      intraocular pressure does not decrease by at least 20% while undergoing treatment with
      latanoprost ?

      Secondary questions:

      1- What is the percentage of glaucoma patients who are resistant to latanoprost ? 2- Which
      prostaglandin is the most effective in decreasing intraocular pressure in cases of resistance
      to latanoprost ?

      Research Project Goals :

      Evaluation of the effectiveness of latanoprost, bimatoprost and travoprost in patients in
      whom latanoprost does not decrease the intraocular pressure by at least 20%. The
      effectiveness of the three prostaglandins will be determined by the IOP : the treatment
      should at least effect a 20% decrease from baseline (IOP measured at time of recruitment),
      with the ultimate aim of attaining the target IOP, which varies depending on the patient.
      Target IOP is based on the severity of optic nerve damage as well as baseline IOP.

      Determine the percentage of patients resistant to prostaglandins. Patients who have not
      responded (as measured by IOP decrease) to more than 2 prostaglandins will be considered
      resistant to this category of hypotensive medications.

      Study design:

      Randomised, open label.

      Study duration:

      Approximately two years.

      POPULATION:

      The target population consists of open angle glaucoma patients, or patients with ocular
      hypertension with an IOP greater than 21 mmHg and who have never undergone treatment for
      glaucoma. Patients must be 18 years or older, capable of giving informed consent in written
      form.

      Sampling

        -  Candidates will be selected from the patient population of the ophthalmology clinic of
           the CHUS hotel-Dieu or from the private practice of Dr. Blondeau

        -  The patients will all be treated with latanoprost for approximately 6 weeks, after which
           only those who have not experienced at least a 20% decrease in their initial IOP and who
           are eligible will be invited to participate in the study.

      Sample size - The sample size estimate is based on the need to obtain a significant decrease
      from baseline IOP at 6 weeks, 2 months and 6 months. Estimating a maximum IOP variation of 2
      mmHg with a standard deviation of +/- 2 mmHg, the necessary sample size to power the study
      (90% with a p &lt; 0.05 using a paired-samples Student T test) is about 47 patients per group.

      Methods of randomization and sample make-up:

      The study will be a randomized and comparative trial taking place over a period of 12 months.
      Patients will be distributed by random lots of 6 (ACBCAB, etc) into 3 different groups after
      a documented non-response (IOP decrease of less than 20%) to latanoprost. Group 1 will remain
      on Latanoprost 0.005%, Group 2 will switch to travoprost 0.004% and Group 3 will switch to
      bimatoprost 0.03%. The dose of each medication will be 1 drop daily HS, which is the usual
      dose in ophthalmological practice and in the scientific literature.

      Intraocular pressure will be measured in the same manner for all patients by applanation
      tonometry.

      Thus, for each study participant:

      Time of IOP measurement IOP value (mmHg) At time of recruitment 6 weeks after 2 months after
      6 months after

      * Therefore, 3 groups of patients will have the same measurements taken.

      Stages of the study:

        1. Patient recruitment:

           - Diagnosis of glaucoma de novo in the outpatient clinic or Dr. Blondeau's office.

           - Patients will be informed about the possibility of resistance to a treatment of 6
           weeks with latanoprost, as well as to its possible benefit. The patient will receive a
           consent form, consisting of an explanation of the study including potential side effects
           of the medications. Patients will be able to take the time to thoroughly read the
           document and to decide whether they wish to participate in the study.

        2. Consent:

           - Informed consent will be obtained by ophthalmologist Dr. Pierre Blondeau or the
           resident in ophthalmology, Zineb Ghali, PGY IV, who will offer clarification and
           explanation to the potential participants if necessary.

        3. Trial Design:

      1. Patients with a diagnosis of primary open-angle glaucoma (POAG) or ocular hypertension
      (OH) but who have never received treatment will be recruited.

      2. Recruited patients will be treated for 6 weeks with latanoprost. This corresponds to the
      time necessary for the molecule to block the all prostaglandin receptors, thus allowing for
      maximum IOP-lowering potential. This period of time was determined by the pharmaceutical
      company that created the molecule and is used by all studies involving the molecule.

      3. Patients who have not experienced a decrease of at least 20% of their baseline IOP and who
      consent to participate will be distributed into 3 different groups (recruitment step). Group
      1 patients will continue to receive latanoprost 0.005%, 1 drop daily HS. The two other groups
      will receive either bimatoprost 0.03% or travoprost 0.004%, 1 drop daily HS. Patients will
      continue to be treated for 4 weeks. Patients will receive instructions regarding medication
      administration and compliance. The medication will be administered every 24 hours between
      20:00 and 22:00. No other IOP-lowering medication will be permitted.

      4. Patients with less than 20% response to initial treatment with latanoprost will be
      randomised into 3 groups corresponding to one of the prostaglandin analogues. IOP will be
      remeasured after 6 weeks in order to evaluate response to the medication. We consider that a
      documented response to treatment consists of a significant decrease in IOP as measured by the
      t-test. If the IOP has not decreased by at least 20% after 1 month of treatment with the
      various prostaglandins, the patient will be excluded from the study, treated with another
      class of hypotensive agent, and receive standard follow-up.

      Security measures:

      The researchers will monitor for possible side effects and other potential problems. To this
      effect, an auxiliary researcher (not yet recruited) as well as a resident in ophthalmology
      (Zineb Ghali) will be available 24 hours a day to address medication side effects or
      unexpected symptoms. If immediate follow-up is required and the patient makes contact during
      business hours, the research team will immediately see the patient. If the patient contacts
      the auxiliary researcher or the resident outside of business hours, he or she will be
      immediately referred to one of the ophthalmology residents on call at the hotel Dieu hospital
      Emergency Department. If necessary, one of the two physician researchers will be available to
      meet with the patient in question.

      This ensures that any adverse reaction will be rapidly treated by the research team. If a
      physician observes undesirable side effects that are attributable to the medication, he or
      she has the duty to discontinue treatment as well as the subject's participation in the
      study. In this case, the physician will ensure continuity of care via another form of
      treatment in order to ensure the patient's recovery.

      Principal dependent variable:

      Intraocular pressure shall be measured with a Goldmann tonometer.

      A drop of fluorescein sodium and benoxinate hydrochloride, USP (0.25%/0.4%) will be instilled
      in the patient's eyes, after which baseline IOP will be measured by Goldmann tonometry. The
      inter-measurement variability is +/- 2mmHg.

      Secondary variables:

        -  Patient age: quantitative

        -  Patient sex: qualitative

        -  Patient race: qualitative

        -  Side effects

           4- Results analysis

      Homogeneity of groups in terms of social demographics will be verified via one-way analysis
      of variance (ANOVA) with Turkey's correction for continuous variables and a chi-square or
      Fisher's exact test for categorical variables. Values discovered to be significant will be
      expressed in the following format: obtained value as well as confidence interval, in order to
      highlight the impact of the particular treatment

      Two-way crossed ANOVA will be used to compare data collected during follow-up with different
      ophthalmological exams, notably the IOP. We will calculate the impact for each period of
      follow-up.

      The incidence of individual side effects will be summarized and compared with a chi-square
      test. Emphasis will be placed on the degree of severity of symptoms caused by the medications
      used. The examined side effects will be those that occur most frequently and are of ocular
      nature.

      There is no interim analysis included in this research project. All statistical tests will
      consider a p-value of less than 0.05 to be statistically significant, i.e. all results will
      be considered statistically significant at the 5% level.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>2 years</time_frame>
    <description>A drop of fluorescein sodium and benoxinate hydrochloride, USP (0.25%/0.4%) will be instilled in the patient's eyes, after which baseline IOP will be measured by Goldmann tonometry. The inter-measurement variability is +/- 2mmHg.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Primary Glaucoma</condition>
  <arm_group>
    <arm_group_label>ophtalmic solution,</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2Î± analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost, bimatoprost, travoprost</intervention_name>
    <description>topic drops, once a day at bedtime, for years</description>
    <arm_group_label>ophtalmic solution,</arm_group_label>
    <other_name>Xalatan</other_name>
    <other_name>Lumigan</other_name>
    <other_name>Travatan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>travoprost, latanoprost and bimatoprost</intervention_name>
    <description>one drop once a day for life</description>
    <arm_group_label>ophtalmic solution,</arm_group_label>
    <other_name>Travatan</other_name>
    <other_name>Xalatan</other_name>
    <other_name>Lumigan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with ocular hypertension or primary open-angle glaucoma who have
             never received treatment.

          -  Age 18 or older and able to give informed consent

        Exclusion Criteria:

          -  Patients with intraocular inflammation of any etiology

          -  Patients with advanced glaucoma, defined by severe optic nerve damage and/or visual
             field deficit.

          -  Patients having had intraocular surgery in the last 4 weeks

          -  Patients undergoing treatment with ophthalmic solution of any kind

          -  Patients unable to give informed consent to participate in the research
             project,including those suffering from psychiatric illness resulting in impaired
             judgement

          -  Monophthalmia or anophthalmia

          -  Pregnant or nursing patients

          -  Patients status post ocular surgery, with the exception of cataract extraction surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Blondeau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre PB Blondeau, MD</last_name>
      <phone>1 (819) 346 1110</phone>
      <phone_ext>28008</phone_ext>
      <email>pierre.blondeau@videotron.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Centre Hostitalier Universitaire de Sherbrooke</name_title>
    <organization>CHUS</organization>
  </responsible_party>
  <keyword>Latanoprost</keyword>
  <keyword>bimatoprost</keyword>
  <keyword>travoprost</keyword>
  <keyword>non responders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

